<DOC>
	<DOCNO>NCT00030446</DOCNO>
	<brief_summary>RATIONALE : Biological therapy erlotinib may interfere growth tumor cell slow growth tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining erlotinib carboplatin may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine erlotinib carboplatin treat patient recurrent ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Erlotinib Carboplatin Treating Patients With Recurrent Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer treat erlotinib carboplatin . - Determine duration stable disease , time progression , response duration patient treat regimen . - Determine toxicity regimen patient . - Correlate level epidermal growth factor receptor tumor expression objective tumor response patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord response prior platinum-containing therapy ( platinum-sensitive , define 6 month since prior therapy platinum agent [ close accrual 2/13/2004 ] , vs platinum-resistant , define less 6 month since prior therapy platinum agent ) . Patients receive carboplatin IV 30 minute day 1 oral erlotinib daily day 1-21 . Treatment repeat every 21 day 6 course . After completion 6 course therapy , patient responsive stable disease may continue receive erlotinib carboplatin absence disease progression unacceptable toxicity . Patients follow 4 week every 3 month thereafter . PROJECTED ACCRUAL : A total 23-60 patient ( 8-30 platinum-sensitive stratum [ close accrual 2/13/2004 ] 15-30 platinum-resistant stratum ) accrue study within 15-23 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer standard curative therapy exist At least 1 measurable lesion At least 20 mm xray , nonspiral CT scan , physical exam OR least 10 mm spiral CT scan Ascites bone metastasis consider measurable disease No abdominal adenocarcinoma unknown origin borderline ovarian tumor No elevate CA 125 evidence disease At least 1 2 prior chemotherapy regimen require First regimen must contain cisplatin carboplatin Switching platinum compound due disease progression failure respond consider 2 regimen Same regimen first secondline therapy consider 2 regimen Responded prior platinumbased firstline chemotherapy No platinumrefractory disease No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal : Creatinine great ULN Cardiovascular : No symptomatic congestive heart failure No unstable angina No cardiac arrhythmia Gastrointestinal : See Surgery No GI tract disease result inability take oral medication require IV alimentation No uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) No active peptic ulcer disease Ophthalmic : No ocular inflammation infection No significant ophthalmologic abnormality , include : History dry eye syndrome , Sj√∂gren 's syndrome , keratoconjunctivitis sicca Severe exposure keratopathy Disorders might increase risk epitheliumrelated complication ( e.g. , bullous keratopathy , aniridia , severe chemical burn , neutrophilic keratitis ) Congenital abnormality ( e.g. , Fuch 's dystrophy ) Abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) Abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biological composition erlotinib No serious illness , medical condition , significant neurologic psychiatric disorder would preclude study therapy No active uncontrolled infection No grade 3 great drugrelated neurotoxicity No malignancy within past 5 year except adequately treat nonmelanoma skin cancer curatively treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy ( except lowdose palliative radiotherapy ) recover Surgery : At least 3 week since prior major surgery ( wound heal must occur ) No prior surgical procedure affect gastrointestinal ( GI ) absorption No concurrent ophthalmic surgery Other : No prior therapy target epidermal growth factor receptor No concurrent anticancer therapy No concurrent investigational agent Concurrent oral anticoagulant ( e.g. , warfarin ) allow provide INR monitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>